Introduction

Goldshield is a profitable, marketing-led, emerging pharmaceutical and healthcare company. Our operations in the United States of America is located in West Palm Beach, Florida. Growth has been rapid and achieved both organically and through astute product acquisition.

The Directors believe that this growth has been driven principally by the Group's marketing skills, customer focus, product ranges and developments, financial controls and extensive staff training. Goldshield aims to service a much broader segment of the pharmaceutical and healthcare markets than many similarly sized pharmaceutical companies.

It sells ethical (prescription) pharmaceuticals, non-prescription medicines, vitamins, minerals and supplements and a wide range of other healthcare products. To service its customers' needs from the highly regulated to the consumer driven markets, Goldshield operates as two divisions, the Pharmaceutical Division and the Healthcare Division.
Goldshield chooses to market products which match its rigorous marketing and financial return criteria. Product licences and brands, where appropriate, are acquired or, increasingly, developed internally. The Directors consider that opportunities exist to acquire further products and develop product line extensions and new chemical entities which meet the Group's investment criteria.

History

The Group was founded by the Company's Chairman, Ajit Patel, together with its Chief Operating Officer, Kirti Patel, and Shane Gogerly, Director of Sales of Pharmaceutical Products. Goldshield commenced trading in 1991 with a range of pharmaceutical and healthcare products.

The first pharmaceutical product was acquired from Glaxo in 1992 and there have been subsequent product acquisitions from SmithKline Beecham, Medeva, Warner Lambert and American Home Products.

Between 1991 and 1993, the Group raised equity finance of £1.0 million from individual investors, many of whom are doctors, pharmacists, or from within the pharmaceutical industry. The Group became profitable in the year ended 31 March 1993.
During 1993, the Group started to sell Healthcare products direct to consumers through mail order, and started the development of its own Pharmaceutical products in 1995. It received its first UK marketing authorisation for a pharmaceutical product licensed to and developed by the Group in 1996.

In 1997, the Healthcare Division's distribution and call-centre and the Group's product development laboratory at Thornton Heath were opened.

In June 1998, the Group floated on the London Stock exchange.

Any comments on this article or you have any news: Click here